Zevra Therapeutics (ZVRA) Times Interest Earned (2014 - 2026)
Zevra Therapeutics (ZVRA) reported Times Interest Earned of $30.48 for Q1 2026, up 1219.15% on a YoY basis from $2.31 in Q1 2025, and up 537.35% quarter-over-quarter from $4.78 in Q4 2025.
Zevra Therapeutics (ZVRA) Times Interest Earned (2014 - 2026) Analysis & Trends
Zevra Therapeutics has reported Times Interest Earned for 13 years, with the latest figure at $30.48 in Q1 2026.
- For the quarter ending Q1 2026, Times Interest Earned rose 1219.15% year-over-year to $30.48; the trailing twelve-month figure through Mar 2026 stood at -$0.7 (up 91.59% YoY), and the FY2025 full-year result was -$7.89, up 33.33% from the prior year.
- Times Interest Earned for Q1 2026 stood at $30.48, up from $4.78 in the prior quarter.
- The five-year high for Times Interest Earned was $30.48 in Q1 2026, with the low at -$70.5 in Q1 2023.
- Historically, Times Interest Earned has averaged -$17.92 across 5 years, with a median of -$15.93 in 2023.
- Annual changes were most pronounced in 2025 — Times Interest Earned tumbled 213.55% — and 2026, when it surged 1219.15%.
- Zevra Therapeutics' Times Interest Earned stood at -$27.8 in 2022, then increased by 27.88% to -$20.05 in 2023, then surged by 64.95% to -$7.03 in 2024, then jumped by 168.05% to $4.78 in 2025, then soared by 537.35% to $30.48 in 2026.
- The last three Times Interest Earned figures came in at $30.48 (Q1 2026), $4.78 (Q4 2025), and $2.02 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3.58 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -258.33 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 11.50 |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 11.79 |
| 10 | Zevra Therapeutics | 796.95 Mn | 596.33 Mn | 34.30 Mn | 30.48 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.48 |
| Dec 31, 2025 | 4.78 |
| Sep 30, 2025 | 2.02 |
| Jun 30, 2025 | -35.36 |
| Mar 31, 2025 | -2.72 |
| Dec 31, 2024 | -7.03 |
| Sep 30, 2024 | -11.81 |
| Jun 30, 2024 | -11.28 |
| Mar 31, 2024 | -27.87 |
| Dec 31, 2023 | -20.05 |
| Sep 30, 2023 | -41.98 |
| Jun 30, 2023 | -31.74 |
| Mar 31, 2023 | -70.50 |
| Dec 31, 2022 | -27.80 |
| Dec 31, 2021 | -568.40 |
| Sep 30, 2021 | -370.33 |
| Jun 30, 2021 | 364.56 |
| Mar 31, 2021 | 34.97 |
| Dec 31, 2020 | -2.76 |
| Sep 30, 2020 | -1.04 |